BioSpace News Archive

Zevra Therapeutics, Inc. announced that leading proxy advisory firms Institutional Shareholder Services and Glass Lewis & Co. have voiced their support for Zevra’s nominees and strategy and found that Mangless’ arguments and nominees were not compelling.

Heron Therapeutics, Inc. (Nasdaq: HRTX) today announced that Craig Collard, Chief Executive Officer of Heron, will participate in a fireside chat on Thursday, April 20, 2023, at 11:45 AM ET at the 22nd Annual Needham Virtual Healthcare Conference.

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the 12 months ended December 31, 2022 and provides a business update.

Universal Diagnostics, a bioinformatics and multi-omics company on a mission to transform cancer into a curable disease, announced the results of a cohort study that highlights the role fragment size, specifically on chromosome 18, plays in early-stage CRC detection.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today presented interim data from its Phase 1 TRAVERSE trial of ALLO-316, the Company’s first AlloCAR TTM investigational product candidate for solid tumors, in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.

Today, Convergent Therapeutics Inc., a clinical-stage biotechnology company, announced the details of a plenary presentation of a dose-escalation study evaluating the efficacy and safety of its lead asset, CONV01-α (225Ac−J591).

PCR Biosystems has launched a new proofreading polymerase mix for NGS library preparation workflows. VeriFi™ Library Amplification Mix combines the powerful and robust performance of VeriFi™ Hot Start Polymerase with greatly reduced GC-dependent bias to push the limits of NGS data.

Eli Lilly and Company announced that it will invest an additional $1.6 billion and add another 200 new jobs at its two new manufacturing sites within LEAP Innovation Park in Boone County, bringing the company’s total commitment to $3.7 billion and up to 700 new jobs.

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced the publication of data from the Company’s GENESIS Phase 3 clinical trial in the peer-reviewed journal Nature Medicine.

Sapphiros is proud to announce it has been selected by the National Institutes of Health Rapid Acceleration of Diagnostics Tech program to develop a high performance, over-the-counter, molecular multiplex respiratory diagnostic test that can rapidly detect RSV, influenza A, influenza B and COVID-19 in a single test.